LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection

BACKGROUND: Respiratory syncytial virus (RSV) is the most common cause of lower respiratory tract infection (LRTI) in infants. Nirsevimab is a single-dose monoclonal antibody with extended half-life that was shown to protect preterm infants 29 to < 35 weeks gestation against RSV LRTI. However, mo...

Descripción completa

Detalles Bibliográficos
Autores principales: Hammitt, Laura, Dagan, Ron, Yuan, Yuan, Cots, Manuel Baca, Bosheva, Miroslava, Mahdi, Shabhir A, Muller, William J, Zar, Heather J, Brooks, Dennis, Grenham, Amy, Hamrén, Ulrika Wählby, Mankad, Vaishali S, Ren, Pin, Takas, Therese, Heinrichs, Jon, Leach, Amanda, Griffin, M Pamela, Villafana, Tonya L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Late Breaker Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644820/
http://dx.doi.org/10.1093/ofid/ofab466.1649

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644820/
http://dx.doi.org/10.1093/ofid/ofab466.1649

Ejemplares similares